Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Wed, 16.10.2024
Formycon AG
Press Release // October 16, 2024
Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
The comparative analytical evaluation results indicate that the proposed Keytruda®-biosimilar FYB206 is structurally and functionally highly similar to the reference [ … ]
Tue, 01.10.2024
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
FYB202 approval in EU and US
Recommendation:
Buy
from:
01.10.2024
Target price:
€82
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000 [ … ]
Mon, 30.09.2024
Formycon AG
Press Release // September 30, 2024
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
OtulfiTMreceived FDA approval for both subcutaneous and intravenous formulations, to treat the same conditions as Stelara®
Approval represents the third successful FDA approval for a Formycon biosimilar, two of them in [ … ]
Fri, 27.09.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Planegg-Martinsried, Germany, September 27, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the U.S. Food and Drug Administration (“FDA”) today approved FYB202/OtulfiTM [ … ]
Fri, 27.09.2024
Formycon AG
Press Release // September 27, 2024Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
FYB202/Otulfi® received European Commission (EC) approval for both subcutaneous and intravenous formulations, providing a high-quality treatment option for European [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Mon, 19.08.2024
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
H1/24 results
Recommendation:
Buy
from:
19.08.2024
Target price:
€80
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analy [ … ]
Tue, 13.08.2024
Formycon AG
Press Release // August 13, 2024
Formycon reports a strong first half-year with multiple milestones achieved
Successful business development characterized by key operational, clinical, and regulatory milestones
Group revenue and EBITDA in line with expectations
Operating results of FYB201 in the first half of the year significantly exceeded ex [ … ]
Wed, 07.08.2024
Formycon AG
Press Release // August 7, 2024
Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2 [ … ]